1.50
-0.05(-3.23%)
Currency In USD
| Previous Close | 1.55 |
| Open | 1.59 |
| Day High | 1.59 |
| Day Low | 1.47 |
| 52-Week High | 2 |
| 52-Week Low | 1.13 |
| Volume | 25,169 |
| Average Volume | 87,436 |
| Market Cap | 73.72M |
| PE | -6 |
| EPS | -0.25 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 1.39 |
| Change | -0.05 |
If you invested $1000 in MediciNova, Inc. (MNOV) 10 years ago, it would be worth $291.83 as of February 21, 2026 at a share price of $1.5. Whereas If you bought $1000 worth of MediciNova, Inc. (MNOV) shares 5 years ago, it would be worth $260.42 as of February 21, 2026 at a share price of $1.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
GlobeNewswire Inc.
Jan 29, 2026 11:00 PM GMT
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of t
2026 New Year’s Greetings from the CEO
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corpo
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
GlobeNewswire Inc.
Dec 18, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successf